Gossamer Bio Inc. (GOSS) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Gossamer Bio (GOSS) Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA
November 12, 2019 7:12 AM EST(Updated - November 12, 2019 7:13 AM EST)
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate the combination of Gossamers investigational product candidate GB1275, the first-in-class oral modulator of CD11b, and Mercks... More
